AUTL
Price
$1.51
Change
-$0.06 (-3.82%)
Updated
Apr 3, 04:59 PM (EDT)
Capitalization
417.82M
28 days until earnings call
SYBX
Price
$1.12
Change
-$0.08 (-6.67%)
Updated
Apr 3, 04:58 PM (EDT)
Capitalization
14.04M
Ad is loading...

AUTL vs SYBX

Header iconAUTL vs SYBX Comparison
Open Charts AUTL vs SYBXBanner chart's image
Autolus Therapeutics
Price$1.51
Change-$0.06 (-3.82%)
Volume$32.59K
Capitalization417.82M
Synlogic
Price$1.12
Change-$0.08 (-6.67%)
Volume$296
Capitalization14.04M
AUTL vs SYBX Comparison Chart
Loading...
AUTL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYBX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AUTL vs. SYBX commentary
Apr 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AUTL is a Buy and SYBX is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 04, 2025
Stock price -- (AUTL: $1.57 vs. SYBX: $1.20)
Brand notoriety: AUTL and SYBX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AUTL: 158% vs. SYBX: 165%
Market capitalization -- AUTL: $417.82M vs. SYBX: $14.04M
AUTL [@Biotechnology] is valued at $417.82M. SYBX’s [@Biotechnology] market capitalization is $14.04M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.64B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AUTL’s FA Score shows that 0 FA rating(s) are green whileSYBX’s FA Score has 0 green FA rating(s).

  • AUTL’s FA Score: 0 green, 5 red.
  • SYBX’s FA Score: 0 green, 5 red.
According to our system of comparison, AUTL is a better buy in the long-term than SYBX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AUTL’s TA Score shows that 4 TA indicator(s) are bullish while SYBX’s TA Score has 4 bullish TA indicator(s).

  • AUTL’s TA Score: 4 bullish, 4 bearish.
  • SYBX’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both AUTL and SYBX are a good buy in the short-term.

Price Growth

AUTL (@Biotechnology) experienced а -3.68% price change this week, while SYBX (@Biotechnology) price change was -7.69% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.57%. For the same industry, the average monthly price growth was -10.69%, and the average quarterly price growth was -14.76%.

Reported Earning Dates

AUTL is expected to report earnings on May 01, 2025.

SYBX is expected to report earnings on Nov 09, 2023.

Industries' Descriptions

@Biotechnology (-8.57% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AUTL($418M) has a higher market cap than SYBX($14M). SYBX YTD gains are higher at: -14.286 vs. AUTL (-33.191). SYBX has higher annual earnings (EBITDA): -23.01M vs. AUTL (-192.51M). AUTL has more cash in the bank: 657M vs. SYBX (18.9M). SYBX has less debt than AUTL: SYBX (0) vs AUTL (52.2M). AUTL has higher revenues than SYBX: AUTL (10.1M) vs SYBX (8K).
AUTLSYBXAUTL / SYBX
Capitalization418M14M2,986%
EBITDA-192.51M-23.01M837%
Gain YTD-33.191-14.286232%
P/E RatioN/AN/A-
Revenue10.1M8K126,250%
Total Cash657M18.9M3,476%
Total Debt52.2M0-
FUNDAMENTALS RATINGS
AUTL vs SYBX: Fundamental Ratings
AUTL
SYBX
OUTLOOK RATING
1..100
1350
VALUATION
overvalued / fair valued / undervalued
1..100
35
Fair valued
87
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9898
PRICE GROWTH RATING
1..100
9380
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AUTL's Valuation (35) in the Biotechnology industry is somewhat better than the same rating for SYBX (87). This means that AUTL’s stock grew somewhat faster than SYBX’s over the last 12 months.

AUTL's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as SYBX (100). This means that AUTL’s stock grew similarly to SYBX’s over the last 12 months.

AUTL's SMR Rating (98) in the Biotechnology industry is in the same range as SYBX (98). This means that AUTL’s stock grew similarly to SYBX’s over the last 12 months.

SYBX's Price Growth Rating (80) in the Biotechnology industry is in the same range as AUTL (93). This means that SYBX’s stock grew similarly to AUTL’s over the last 12 months.

SYBX's P/E Growth Rating (100) in the Biotechnology industry is in the same range as AUTL (100). This means that SYBX’s stock grew similarly to AUTL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AUTLSYBX
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
86%
Momentum
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
88%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
86%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
89%
Advances
ODDS (%)
Bullish Trend 7 days ago
84%
Bullish Trend 18 days ago
84%
Declines
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 2 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
89%
Bullish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
87%
View a ticker or compare two or three
Ad is loading...
AUTL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYBX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RYBIX76.26N/A
N/A
Rydex Basic Materials Inv
VCIEX8.32N/A
N/A
VALIC Company I International Eqs Idx
VLCGX15.85N/A
N/A
VALIC Company I Large Capital Growth
AEURX8.62N/A
N/A
American Century Equity Income R
SREAX12.96N/A
N/A
PGIM Select Real Estate A